Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DNDN - Dendreon Corp. -- Ignore unavailable to you. Want to Upgrade?

To: brk who wrote (100)	12/10/2000 9:26:49 PM
From: Elmer	Read Replies (1) \| Respond to of 751

Toth has made some good calls like when Imclome got to submit for a license after completing only phase II trials. Toth said the FDA would agree and the stock went from $60 to split adjusted $100 now. If you want a test of his accuracy, watch Maxim Pharm tomorrow and ILXO on Tuesday. Toth says 60% likelyhood of success for Maxim and 90% for ILXO. They are both before FDA panels. MAXM is very interesting as it has a huge short interest and should have a big move if they get approval. I'm going to go long the stock and buy Dec. at the money puts. If they get approval, the cost of the puts won't matter. If they don't, I go back under my desk.